Unknown

Dataset Information

Liquid biopsy-based targeted gene screening highlights tumor cell subtypes in patients with advanced prostate cancer.


ABSTRACT: Prostate cancer (PCa) clinical heterogeneity underscores tumor heterogeneity, which may be best defined by cell subtypes. To test if cell subtypes contributing to progression can be assessed noninvasively, we investigated whether 14 genes representing luminal, neuroendocrine, and stem cells are detectable in whole blood RNA of patients with advanced PCa. For each gene, reverse transcription quantitative polymerase chain reaction assays were first validated using RNA from PCa cell lines, and their traceability in blood was assessed in cell spiking experiments. These were next tested in blood RNA of 40 advanced PCa cases and 40 healthy controls. Expression in controls, which was low or negative, was used to define stringent thresholds for gene overexpression in patients to account for normal

SUBMITTER: Derderian S 

PROVIDER: S-EPMC9652435 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature